New artificial intelligence (AI) technology that detects subtle changes in the retina could prove a game-changer in helping millions of people avoid vision loss or blindness.
Dec 7, 2022
0
25
Retinitis pigmentosa is a degenerative disease affecting the photoreceptor cells in the retina, known as cones and rods. Of genetic origin, this disease first affects vision in low light conditions, and progressively peripheral ...
May 31, 2022
0
39
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ongoing treatment. Retinal ...
Apr 21, 2022
0
14
Patients with high cholesterol and triglycerides who underwent spinal, cardiac or orthopedic surgery were at greater risk of waking up blind, reports a new Northwestern Medicine study.
Dec 2, 2021
0
28
(HealthDay)—The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug ...
Sep 24, 2021
0
11
(HealthDay)—Filling a prescription for female hormone therapy (FHT) is not associated with an increased risk for retinal artery occlusion (RAO) or retinal vein occlusion (RVO), according to a study published online Nov. ...
Nov 17, 2020
0
2
Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.
Jun 29, 2020
0
177
(HealthDay)—Retinal vein occlusion (RVO) is associated with an increased risk for cardiovascular events and all-cause mortality, according to a review published in the September issue of Retina.
Sep 9, 2019
0
3
A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed model of central retinal vein occlusion (CRVO) in mice ...
Jan 15, 2019
0
1
(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic ...
Mar 26, 2018
0
2
